Intraocular Pressure

New devices, advancements in technology and unique MIGS approaches provide an expansive landscape for surgeons to manage IOP without invasive incisional surgeries or increasing medication burdens.

The accompanying cover story is a good summary of the current microinvasive, or minimally invasive, glaucoma surgery devices.

The withdrawal of the CyPass (Alcon) removed the one drainage device that shunted fluid to the suprachoroidal space, and it has not been replaced to date. This mechanism was unique and provided a significant benefit for many patients with uncontrolled IOP. Corneal endothelial health is important, and the safety data elucidating the long-term risk in some patients should not be discounted. In my opinion, solely as a practitioner and not as a regulatory specialist, I would have preferred for the new safety data to result in greater education regarding proper positioning of the device and a recommendation for use in later-stage disease.

Patients with glaucoma treated with the Omni surgical system in the GEMINI study experienced a statistically significant reduction in both IOP and IOP-lowering medications.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Sight Sciences has initiated patient enrollment in the ORION clinical study of the Omni surgical system in pseudophakic eyes, according to a press release.

A 26-year-old white female presented for a comprehensive eye examination. No visual or ocular complaints were reported. The patient described good vision with her current spectacles. She mentioned that previous eye care practitioners told her that she had “macular degeneration” in her right eye.

A 74-year-old African American man presented for a glaucoma work-up after being identified as a glaucoma suspect due to enlarged cup-to-disc ratios at his annual exam a month prior.

MicroOptx has completed enrollment in the initial phase of its FDA investigational device exemption clinical trial of the Beacon aqueous microshunt, according to a press release.

YAG laser vitreolysis alleviated symptomatic floaters in select patients whose treatable opacities were identified and followed by swept-source OCT of the vitreous.